Clinical Trial Update: The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 trial evaluating Fx-1006A for stabilizing transthyretin and improving clinical outcomes in patients with transthyretin amyloid cardio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Fx-1006A

Snippet

Sponsor: Pfizer | Conditions: Cardiomyopathy | Phase 2 | Status: COMPLETED | Results posted: 2012-12-18